Advertisement
ALNY or JNJ or ZTS
Which Stock Would AI Choose? Alnylam Pharmaceuticals (ALNY) vs. Johnson & Johnson (JNJ) vs. Zoetis (ZTS) Stock Comparison
Key Takeaways
- ALNY exhibits robust revenue growth from RNAi therapeutics like AMVUTTRA, with YTD returns around -21% but strong 1-year gains of ~18%, trading at a high P/E of ~140 amid pipeline momentum.
- JNJ delivers stability with YTD gains of ~17%, a reasonable P/E near 22, and recent FDA approval for ICOTYDE boosting its immunology portfolio, supported by diversified revenue exceeding $94B.
- ZTS faces headwinds with YTD declines of ~10% and 1-year drops of ~31%, linked to safety concerns on Librela, though fundamentals remain solid with $9.5B revenue and P/E around 19.
- JNJ leads in market cap (~$584B) and relative performance, offering lower volatility (beta 0.33) versus biotech peers.
- All three operate in animal/human health innovation, but JNJ's broad exposure contrasts ALNY's high-growth RNAi focus and ZTS's livestock/companion animal niche.
- Recent market activity shows ALNY volatile post-earnings, JNJ resilient, and ZTS pressured by sector rotation.
Introduction
This stock comparison evaluates ALNY, a leader in RNA interference (RNAi) therapeutics for rare diseases; JNJ, a diversified healthcare giant spanning pharmaceuticals and MedTech; and ZTS, the world's top animal health company focusing on vaccines and medicines for pets and livestock. Investors seeking growth in biotech innovation, stability in established blue-chips, or defensive plays in veterinary care will find value in analyzing their recent performance, business drivers, and relative positioning amid evolving market sentiment and sector dynamics.
ALNY Overview and Recent Performance
Alnylam Pharmaceuticals (ALNY) pioneers RNAi therapeutics, silencing disease-causing genes for conditions like ATTR amyloidosis and primary hyperoxaluria. With a market cap around $42B, the company reported full-year 2025 net product revenues of $3B, up 81% year-over-year, driven by AMVUTTRA and ONPATTRO uptake. Recent weeks saw shares hover near $316, down ~5% monthly but up ~18% annually, reflecting post-earnings volatility after Q4 non-GAAP EPS of $1.25 beat estimates despite a slight revenue miss. Sentiment has been influenced by the "Alnylam 2030" strategy targeting $4.9-$5.3B in 2026 revenues (71% growth midpoint), partnerships like Viz.ai for ATTR-CM detection, and a $1.1B Tenaya collaboration, underscoring pipeline expansion despite high valuation sensitivity (P/E ~140).
JNJ Overview and Recent Performance
Johnson & Johnson (JNJ), with a $584B market cap, operates in Innovative Medicine and MedTech, delivering products for oncology, immunology, and orthopedics. Trailing twelve-month revenue reached $94B, up 9% quarterly. Shares traded around $242, up ~1% daily and ~17% YTD, outperforming peers amid broader market dips. Key influences include FDA approval of ICOTYDE (icotrokinra), the first oral IL-23R-targeted peptide for moderate-to-severe plaque psoriasis in adults and pediatrics (12+ years, ≥40kg), enhancing its immunology franchise post-Stelara. A $500M R&D co-funding for JNJ-4804 further bolsters growth prospects, supporting steady momentum and a P/E near 22, though litigation lingers as a risk factor.
ZTS Overview and Recent Performance
Zoetis (ZTS), market cap ~$48B, leads animal health with vaccines, medicines, and diagnostics for companion animals and livestock across 100+ countries. Fiscal 2025 revenue hit $9.5B, up 2.3% with gross margins at 72%. Shares fell to ~$116, down ~12% monthly, ~10% YTD, and ~31% annually, underperforming amid sector pressures. Recent market activity reflects safety concerns over osteoarthritis drug Librela, contributing to steeper declines than the S&P 500. Broader sentiment shifts from regulatory scrutiny and competitive dynamics have weighed on pricing power, though core fundamentals like expanding margins and share buybacks provide a base for potential stabilization.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the top-performing AI trading bots from hundreds available on the platform, which collectively trade thousands of tickers across stocks, ETFs, and crypto. Only those demonstrating superior adaptability to current market conditions—factoring in volatility, sector rotations, and momentum—earn a spot in this dynamic section. Bots vary widely in strategies (e.g., pattern recognition, trend following), timeframes (5-min to daily), and stats like annualized returns up to 227%, win rates of 70-95%, and profit factors exceeding 3.0. For instance, top agents have posted 171% 30-day annualized returns with 100% win rates on select trades, while others achieve 85-90% success in leveraged ETFs. Explore these high-conviction options to enhance your trading edge.
Head-to-Head Comparison
ALNY’s biotech model emphasizes high-growth RNAi innovation for rare diseases, contrasting JNJ’s diversified stability across human pharma/MedTech and ZTS’s animal health focus. Growth drivers differ: ALNY boasts 81% revenue surge via TTR therapies; JNJ 9% via blockbusters like ICOTYDE; ZTS modest 2% amid vet market saturation. Recent momentum favors JNJ (17% YTD) over ALNY (-21%) and ZTS (-10%), with risks higher for ALNY (clinical/regulatory) and ZTS (product safety). All share healthcare exposure but vary in sector: human rare/prevalent vs. veterinary. Valuation sensitivity peaks at ALNY (P/E 140), moderate at ZTS (19), balanced at JNJ (22). Sentiment tilts toward JNJ’s resilience amid biotech volatility.
Tickeron AI Verdict
Tickeron’s AI currently favors JNJ due to its trend consistency, lower volatility, fresh catalysts like ICOTYDE approval, and superior relative YTD positioning versus ALNY’s earnings dips and ZTS’s safety-driven declines. Probabilistic edge stems from diversified stability and momentum in recent market activity.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALNY’s FA Score shows that 1 FA rating(s) are green whileJNJ’s FA Score has 3 green FA rating(s), and ZTS’s FA Score reflects 2 green FA rating(s).
- ALNY’s FA Score: 1 green, 4 red.
- JNJ’s FA Score: 3 green, 2 red.
- ZTS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALNY’s TA Score shows that 3 TA indicator(s) are bullish while JNJ’s TA Score has 1 bullish TA indicator(s), and ZTS’s TA Score reflects 4 bullish TA indicator(s).
- ALNY’s TA Score: 3 bullish, 5 bearish.
- JNJ’s TA Score: 1 bullish, 6 bearish.
- ZTS’s TA Score: 4 bullish, 6 bearish.
Price Growth
ALNY (@Biotechnology) experienced а +1.02% price change this week, while JNJ (@Pharmaceuticals: Major) price change was -1.88% , and ZTS (@Pharmaceuticals: Generic) price fluctuated -0.07% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.04%. For the same industry, the average monthly price growth was -3.95%, and the average quarterly price growth was +5.21%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.86%. For the same industry, the average monthly price growth was -2.62%, and the average quarterly price growth was +6.54%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +3.18%. For the same industry, the average monthly price growth was +3.88%, and the average quarterly price growth was -0.58%.
Reported Earning Dates
ALNY is expected to report earnings on Apr 30, 2026.
JNJ is expected to report earnings on Apr 14, 2026.
ZTS is expected to report earnings on May 07, 2026.
Industries' Descriptions
@Biotechnology (+1.04% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Major (-0.86% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Pharmaceuticals: Generic (+3.18% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| ALNY | JNJ | ZTS | |
| Capitalization | 43B | 574B | 49.6B |
| EBITDA | 631M | 41.1B | 4.07B |
| Gain YTD | -18.997 | 15.838 | -5.926 |
| P/E Ratio | 138.24 | 21.62 | 19.58 |
| Revenue | 3.71B | 94.2B | 9.47B |
| Total Cash | 2.91B | 20.1B | 2.31B |
| Total Debt | 1.28B | 47.9B | 9.24B |
ALNY | JNJ | ZTS | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 66 | 59 | 7 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 94 Overvalued | 22 Undervalued | 29 Undervalued | |
PROFIT vs RISK RATING 1..100 | 50 | 9 | 100 | |
SMR RATING 1..100 | 15 | 27 | 16 | |
PRICE GROWTH RATING 1..100 | 62 | 42 | 61 | |
P/E GROWTH RATING 1..100 | 100 | 78 | 86 | |
SEASONALITY SCORE 1..100 | 50 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
JNJ's Valuation (22) in the Pharmaceuticals Major industry is in the same range as ZTS (29) in the Pharmaceuticals Generic industry, and is significantly better than the same rating for ALNY (94) in the Biotechnology industry. This means that JNJ's stock grew similarly to ZTS’s and significantly faster than ALNY’s over the last 12 months.
JNJ's Profit vs Risk Rating (9) in the Pharmaceuticals Major industry is somewhat better than the same rating for ALNY (50) in the Biotechnology industry, and is significantly better than the same rating for ZTS (100) in the Pharmaceuticals Generic industry. This means that JNJ's stock grew somewhat faster than ALNY’s and significantly faster than ZTS’s over the last 12 months.
ALNY's SMR Rating (15) in the Biotechnology industry is in the same range as ZTS (16) in the Pharmaceuticals Generic industry, and is in the same range as JNJ (27) in the Pharmaceuticals Major industry. This means that ALNY's stock grew similarly to ZTS’s and similarly to JNJ’s over the last 12 months.
JNJ's Price Growth Rating (42) in the Pharmaceuticals Major industry is in the same range as ZTS (61) in the Pharmaceuticals Generic industry, and is in the same range as ALNY (62) in the Biotechnology industry. This means that JNJ's stock grew similarly to ZTS’s and similarly to ALNY’s over the last 12 months.
JNJ's P/E Growth Rating (78) in the Pharmaceuticals Major industry is in the same range as ZTS (86) in the Pharmaceuticals Generic industry, and is in the same range as ALNY (100) in the Biotechnology industry. This means that JNJ's stock grew similarly to ZTS’s and similarly to ALNY’s over the last 12 months.
| ALNY | JNJ | ZTS | |
|---|---|---|---|
| RSI ODDS (%) | N/A | N/A | 1 day ago 55% |
| Stochastic ODDS (%) | 1 day ago 59% | 1 day ago 52% | 1 day ago 68% |
| Momentum ODDS (%) | 1 day ago 66% | 1 day ago 47% | 1 day ago 54% |
| MACD ODDS (%) | 1 day ago 68% | 1 day ago 52% | 1 day ago 65% |
| TrendWeek ODDS (%) | 1 day ago 71% | 1 day ago 40% | 1 day ago 61% |
| TrendMonth ODDS (%) | 1 day ago 69% | 1 day ago 42% | 1 day ago 63% |
| Advances ODDS (%) | 18 days ago 76% | 3 days ago 44% | 3 days ago 52% |
| Declines ODDS (%) | 10 days ago 66% | 5 days ago 41% | 16 days ago 58% |
| BollingerBands ODDS (%) | 1 day ago 73% | N/A | 1 day ago 62% |
| Aroon ODDS (%) | 1 day ago 78% | 1 day ago 34% | 1 day ago 65% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GMEU | 10.30 | 0.33 | +3.31% |
| T-Rex 2X Long GME Daily Target ETF | |||
| IBIG | 26.27 | N/A | -0.01% |
| iShares iBonds Oct 2030 Term Tips ETF | |||
| IJS | 122.88 | -0.37 | -0.30% |
| iShares S&P Small-Cap 600 Value ETF | |||
| HYBL | 27.85 | -0.09 | -0.32% |
| State Street® Blackstone High Income ETF | |||
| AAPX | 26.70 | -0.11 | -0.41% |
| T-Rex 2X Long Apple Daily Target ETF | |||
ZTS and
Correlation & Price change
A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with ELAN. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then ELAN could also see price increases.
| Ticker / NAME | Correlation To ZTS | 1D Price Change % | ||
|---|---|---|---|---|
| ZTS | 100% | -1.78% | ||
| ELAN - ZTS | 52% Loosely correlated | -1.41% | ||
| VTRS - ZTS | 44% Loosely correlated | -1.03% | ||
| PRGO - ZTS | 41% Loosely correlated | +2.45% | ||
| HLN - ZTS | 40% Loosely correlated | -0.40% | ||
| PAHC - ZTS | 39% Loosely correlated | -2.03% | ||
More | ||||